Stock Price Quote

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE12076.9555 (+0.46 %)
PREV CLOSE ( ) 12021.95
OPEN PRICE ( ) 12010.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2044
TODAY'S LOW / HIGH ( )11814.05 12793.00
52 WK LOW / HIGH ( )5557 18089.55
NSE12071.552.35 (+0.02 %)
PREV CLOSE( ) 12069.20
OPEN PRICE ( ) 12037.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 12071.55 (139)
VOLUME 74748
TODAY'S LOW / HIGH( ) 11734.85 12797.40
52 WK LOW / HIGH ( )5540.1 18100
1D 1M 3M 1Y 3Y 5Y
JavaScript chart by amCharts 3.4.2Show all

STOCK SUMMARY

Incorporation Year : 07-01 1984
Management Info
Davuluri Rama Mohan Rao - Chairman Davuluri Saharsh Rao - Managing Director
Registered Office

Address 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone 040-67611600 / 67611700

Email neuland@neulandlabs.com

Website www.neulandlabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

27Feb Neuland Laboratories informs about dis
Neuland Laboratories has informed that the exchange has received the dis..
25Feb Neuland Laboratories informs about dis
Neuland Laboratories has informed that the exchange has received the dis..
22Jan Neuland Laboratories leads the gainers
Neuland Laboratories is currently trading at Rs. 13838.00, up by 641.95..
03Jan Neuland Laboratories informs about cer
Neuland Laboratories has informed that it enclosed certificate as requir..
24Dec Neuland Laboratories informs about upd
Pursuant to Company’s Insider Trading Code read with SEBI PIT Regulation..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit1013.942995.96
Gross Profit 1275.45 4007.69
Operating Profit 902.824744.65
Net Sales 3980.3215585.8

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  30730.65 (0.48%)
M.Cap ( in Cr)65300.49
Procter&Gamble Healt (BSE)
peergroup  5142.30 (2.90%)
M.Cap ( in Cr)8535.90
Astrazeneca Pharma I (BSE)
peergroup  8606.35 (1.32%)
M.Cap ( in Cr)21515.88
Suven Pharma (BSE)
peergroup  1159.80 (4.55%)
M.Cap ( in Cr)29524.44
AMI Organics (BSE)
peergroup  2441.55 (1.85%)
M.Cap ( in Cr)9994.35

Shareholding Pattern

MUTUAL FUNDS/UTI 6.29%
NON-INSTITUTION 33.97%
PROMOTERS 32.68%
FI/BANKS/INSURANCE 0.57%
GOVERNMENT 0.4%
FII 0%

About Neuland Laboratories Ltd.

Neuland Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 12076.95. Its current market capitalisation stands at Rs 15494.59 Cr. In the latest quarter, company has reported Gross Sales of Rs. 15585.81 Cr and Total Income of Rs.15711.25 Cr. The company's management includes Christopher M Cimarusti, Sarada Bhamidipati, Pallavi Joshi Bakhru, Sugata Sircar, Prasad Raghava Menon, Homi Rustam Khusrokhan, Nirmala Murthy, Davuluri Saharsh Rao, Davuluri Sucheth Rao, Davuluri Rama Mohan Rao.

It is listed on the BSE with a BSE Code of 524558 , NSE with an NSE Symbol of NEULANDLAB and ISIN of INE794A01010. It's Registered office is at 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee HillsHyderabad-500033, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are KS Aiyar & Co, MSKA & Associates, Walker Chandik & Co LLP, Walker Chandiok & Co LLP

1.NSE exchange is Stopping the facility of Stop-Loss Market (SL-M) orders In option trade from 27th Sept 2021 to avoid freak trades and reduce its impact significantly. 2. Introduction of T+1 rolling settlement on optional basis. Stock Exchange may choose to offer T+1 settlement cycle. There shall be no netting between T+1 and T+2 settlements. Circular provisions come into force with effect from Jan: @SEBI_India 3. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. 4. Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 5. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month. 6.Do not share sensitive information like User ID, Password, OTP, etc., with anyone. Regards, Nirmal Bang.
1.NSE exchange is Stopping the facility of Stop-Loss Market (SL-M) orders In option trade from 27th Sept 2021 to avoid freak trades and reduce its impact significantly. 2. Introduction of T+1 rolling settlement on optional basis. Stock Exchange may choose to offer T+1 settlement cycle. There shall be no netting between T+1 and T+2 settlements. Circular provisions come into force with effect from Jan: @SEBI_India 3. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. 4. Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 5. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month. 6.Do not share sensitive information like User ID, Password, OTP, etc., with anyone. Regards, Nirmal Bang.

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.
Close X
OPEN

DEMAT ACCOUNT

AND START YOUR

INVESTMENT

JOURNEY WITH US
(You will receive a Call & SMS from our end)
Popup-Character

Disclaimer: NIRMAL BANG SECURITIES PVT LTD: Investment in Securities market are subject to market risks. Read all the related documents carefully before investing. Please read the Do’s and Don’ts prescribed by the Commodity Exchange before trading. We do not offer PMS Service for the Commodity segment. Opening of account will not guarantee allotment of shares in IPO. Investors are requested to do their own due diligence before investing in any IPO. The securities quoted are exemplary and are not recommendatory. BSE (Member ID- 498): INB011072759, INF011072759, Exchange Registered Member in CDS; NSE MEMEBR ID- 09391): INB230939139, INF230939139, INE230939139; MSEI Member ID-1067): INB260939138, INF260939138, INE260939139: Single Registration No. INZ000202536, PMS Registration No: INP000002981; Research Analyst Registration No: INH000001766; NSDL/ CDSL: IN-DP-CDSL 37-99; Exchange Member ID: MCX - 56460, NCDEX - 1268, ICEX – 2073. Regd. Office: B-2, 301/302, 3rd Floor, Marathon Innova, Off Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013. Tel: 62738000/01; Fax: 62738010 | *NIRMAL BANG NIVESHALAYA PVT LTD: ARN – 111233, Mutual Fund Distributor. Mutual Fund Investments are subject to market risks. Please read the offer documents carefully before Investing.” Regd. Office: B - 201, Khandelwal House, Poddar Road, Near Poddar Park, Malad (East). Mumbai – 400097. | **NIRMAL BANG INSURANCE BROKING PVT LTD: IRDAI Registration No: 795 and Registration Code For the Insurance Broker: IRDAI/DB889/2021. Insurance is the subject matter of the solicitation. For more details on policy terms, conditions, exclusions, limitations, please refer/read policy brochure carefully before concluding sale.